Vernalis plc, of Winnersh, U.K., reported the results from a phase Ib/II proof-of-concept study of V81444, an A2A antagonist which has potential applications for the treatment of Parkinson's disease, attention deficit hyperactivity disorder (ADHD) and other disorders of the central nervous system.